MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutations
Jan Trøst Jørgensen,Edyta M. Urbanska,Jens Mollerup
DOI: https://doi.org/10.21037/tlcr-24-98
2024-04-26
Translational Lung Cancer Research
Abstract:Jan Trøst Jørgensen 1 , Edyta M. Urbanska 2 , Jens Mollerup 3 1 Medical Sciences, Dx-Rx Institute, Fredensborg, Denmark; 2 Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; 3 Pathology Division, Agilent Technologies Denmark ApS, Glostrup, Denmark Comment on: Mazieres J, Paik PK, Garassino MC, et al . Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial. JAMA Oncol 2023;9:1260-6. Keywords: Non-small-cell lung cancer (NSCLC); MET exon 14-skipping mutations ( MET ex14); tepotinib; capmatinib; companion diagnostics Submitted Jan 28, 2024. Accepted for publication Mar 29, 2024. Published online Apr 25, 2024. doi: 10.21037/tlcr-24-98 Non-small-cell lung cancer (NSCLC) is a heterogeneous disease with several histological subtypes and a range of known driver molecular alterations. Over the past few decades, the treatment landscape for NSCLC has undergone significant transformation owing to the emergence of targeted therapies related to specific oncogenic drivers such as ALK , BRAF , EGFR , HER2 , KRAS , NTRK , RET , ROS1 , and recently MET exon 14-skipping mutations ( MET ex14) (1). The occurrence of MET ex14 is relatively rare in NSCLC, with a frequency of 2–4% depending on the histological subtype (2,3). The frequency in patients with pulmonary pleomorphic carcinomas was reported to be 17.4%, in sarcomatoid histology 12%, followed by those with adenocarcinoma and squamous cell carcinoma, with frequencies of 2.4% and 1.3%, respectively. Additionally, patients with NSCLC and MET ex14 tend to be older, with only minor differences with respect to sex or smoking history (2). Mutations leading to MET ex14 typically result in the loss of CBL ubiquitin ligase binding sites on the MET receptor and reduced ubiquitination, allowing for sustained activation of the receptor (4). Different other MET dysregulations, such as gene amplification or fusion, mutations localized in the kinase domain, and protein overexpression, may lead to the oncogenic activation of MET-mediated signaling (1). MET ex14 is prone to emerge in the absence of other oncogenic alterations. However, co-existing mutations in TP53 and MET amplification were identified in 56% and 13.3% of patients, respectively (5). MET amplification has also been recognized as a mechanism for acquired resistance to EGFR tyrosine kinase inhibitors (TKI) in patients with EGFR -mutated NSCLC (6,7). The main objective of this Editorial Commentary was to present and discuss long-term follow-up data for tepotinib, a selective MET inhibitor, in NSCLC patients with MET ex14 mutations from the VISION Phase II clinical trial. The treatment of patients with NSCLC harboring MET ex14 has undergone significant changes in recent years, with the regulatory approval of several selective MET-TKIs. These compounds specifically bind to the intracellular part of the MET receptor and inhibit its kinase activity and downstream signaling pathways (8,9). Initial data were available for crizotinib, where in the PROFILE 1001 study, 18 NSCLC patients with MET ex14 had an objective response rate (ORR) of 44%. Based on this data, the US Food and Drug Administration (FDA) granted a breakthrough designation in 2018. More mature data published in 2020 showed though a lower ORR of 32%, median progression-free survival (PFS) of 7.3 months and a median overall survival (OS) of 20.5 months (10). The first approval of a more promising MET-TKI came from Japan in 2020, when tepotinib was approved for the treatment of patients with unresectable, advanced, or recurrent NSCLC with MET ex14 (2). In 2021, a similar approval came from the FDA and the European Medicines Agency (EMA) in 2022 (8,11). Tepotinib is not the only selective MET-TKI that has regulatory approval. Capmatinib obtained approval by FDA in 2020, and subsequently by EMA in 2022 (9,12). Savolitinib is another selective MET-TKI that has been approved in China for the treatment of patients with advanced NSCLC with MET ex14 (13). This approval was based on the results of a phase II trial (NCT02897479) in NSCLC patients with MET ex14, who had progressed on or were unable to tolerate platinum-based chemotherapy. The ORR was 49.2% after a median follow-up of 17.6 months, and all responses were partial. Savolitinib showed similar ORR in first line as in later lines, 46.4% versus 40.5%, and a PFS of 6.9 months in both groups, regardless of the treatment line and histologic subtypes such as pulmonary sarcomatoid carcinoma or other -Abstract Truncated-
oncology,respiratory system